$BRKR News

Citigroup Maintains Neutral on Bruker, Raises Price Target to $60

Leerink Partners Maintains Outperform on Bruker, Raises Price Target to $70

Guggenheim Maintains Buy on Bruker, Raises Price Target to $70

JPMorgan Maintains an “Overweight rating” on Bruker Corporation (BRKR)

Bruker (BRKR) Stock Trades Up, Here Is Why

Barclays Maintains Overweight on Bruker, Raises Price Target to $60

Bruker Corp Files Prospectus For Mixed Shelf Offering, Size Not Disclosed

What Bruker (BRKR)'s Expanded Diagnostics and Energy-Research Tools Portfolio Means For Shareholders

Bruker Corporation (BRKR) Presents at Jefferies Global Healthcare Conference 2026 Transcript

Is Bruker Corporation (BRKR) A Good Stock To Buy Now?

Bruker Signals Growth Pivot as Semiconductor and Overseas Orders Gain Steam

Bruker (BRKR) Up 37.1% Since Last Earnings Report: Can It Continue?

Bruker Showcases Expanding Microbiology & Infection Diagnostics Portfolio at ASM Microbe 2026

Bruker's Microbiology & Infection Diagnostic Division Showcases Expanding Portfolio, Innovations Throughout Microbial Identification, Sepsis Diagnostics, Molecular Testing, And NGS Workflows

Bruker Launches new timsMRMS Mass Spectrometry Platform for Unique Ultra-Complex Mixture Applications in the Energy Industry

Wolfe Research Assumes Bruker at Peer Perform

Bruker Announces Major Strides in 4D Proteomics Performance, Further Advances In Intact and Top-Down Functional Proteoform Analysis, and Innovations in Hybrid Qual/Quant 4D Metabolomics – all to Enable Deeper Insights into Disease Biology

At ASMS, Bruker Launches TimsMRMS System, Focused On Trapped Ion Mobility Separation To Ultra-high-resolution Magnetic Resonance Mass Spectrometry

Q1 Earnings Highs And Lows: Bruker (NASDAQ:BRKR) Vs The Rest Of The Research Tools & Consumables Stocks

Bruker: Earnings Recovery Priced In, Growth Still Missing